

Significant improvement of quality of life during clinical use of a vitamin preparation — a post marketing surveillance with 3179 patients

Bettina Vinson, K. Zeller

**Steigerwald Arzneimittelwerk GmbH, Havelstr. 5,
64295 Darmstadt, Germany**

In this post marketing surveillance 3179 patients suffering from weak condition after surgery or disease, liver parenchyma diseases, neuralgia, peripheral circulation problems, herpes zoster or other indications were treated with Eukalisan N®, which is a combination preparation for s.c. injection of the vitamins cyanocobalamin, nicotinamide and rutoside and the local anaesthetic procaine. Observation period was 8 weeks. Efficacy of treatment for all indications was assessed by a questionnaire of quality of life (SF 12) estimating psychic and physical condition. Efficacy and tolerability were also assessed directly by the physicians and the patients. Also duration of use and safety parameters were evaluated.

Most of the patients (46.1 %) were treated for weak condition after surgery and diseases, for neuralgia (13.6%) and for other indications (13.2%). The sum scales of the psychic and physical condition (SF-12 questionnaire) showed overall significant improvement for quality of life in all indications comparing start of therapy and after 8 weeks of treatment. There has been still an increasing trend for the sum scales in all indications and most of the patients (66.2%) were treated further on with Eukalisan N®. 81.4% of the physicians and 80.2% of the patients rated efficacy as good or excellent. Tolerability was assessed as good or excellent by 96.5% of the physicians and 93.9% of the patients. There have been 6 adverse events reported where no adverse event has been serious or was unknown.

Conclusively, in this post marketing surveillance Eukalisan N® has been shown to be a safe and efficacious medication for treatment of the listed indications, especially weak conditions after surgery or diseases.